BioVex Ltd

BioVex is a Phase II clinical-stage biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Our pipeline of cancer product candidates is built on first-in-class oncolytic virus technology that replicates and spreads within solid tumors, causing the death of cancer cells, accompanied by the induction of a systemic immune response.